Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861021 | 0.87 | PIP5K1C (0.46) | MAPK10SIRT2SIRT1L3MBTL1PIP5K1C | |
| SCHEMBL4333000 | 0.85 | MAPK1 (0.41) | MAPK1SLC6A3SCN9A | |
| SCHEMBL13198243 | 0.85 | MAPK1 (0.41) | MAPK1SLC6A3SCN9A | |
| SCHEMBL13198310 | 0.84 | MAPK10 (0.47) | MAPK10SIRT2SIRT1POLBRECQL | |
| SCHEMBL4337567 | 0.84 | MAPK10 (0.47) | MAPK10SIRT2SIRT1POLBRECQL | |
| SCHEMBL4339195 | 0.84 | SIRT2 (0.40) | SIRT2SIRT1POLBPIP5K1CMAPK1 | |
| SCHEMBL2865451 | 0.81 | MAPK10 (0.42) | MAPK10SIRT2SIRT1PIP5K1CJAK2 | |
| SCHEMBL4343378 | 0.80 | KMT2A (0.47) | POLB | |
| SCHEMBL2857820 | 0.79 | ACLY (0.42) | MAPK10SIRT2SIRT1JAK2JAK3 | |
| SCHEMBL13635937 | 0.77 | MAPK10 (0.40) | MAPK10SIRT2SIRT1PIP5K1CSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK10 29/4885SIRT2 1519/4885SIRT1 793/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK10 29/4885SIRT2 1519/4885SIRT1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.